导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.80% | 3055/4773 |
| 近一周 | -1.79% | 3396/5467 |
| 近一月 | -2.59% | 1001/5421 |
| 近一季 | -0.93% | 1091/5238 |
| 近半年 | -1.05% | 1846/4931 |
| 近一年 | 0.50% | 2477/4400 |
| 近两年 | 35.49% | 2086/2954 |
| 近三年 | 22.34% | 1380/2253 |
| 成立以来 | 44.73% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.03% 4006/4961 |
6.77% 2796/5312 |
- - |
- - |
| 2025 | 15.54% 2535/4813 |
-0.59% 2314/3635 |
2.75% 1390/4076 |
10.69% 3258/4524 |
2.19% 1052/4813 |
| 2024 | 17.12% 727/3463 |
3.35% 589/2808 |
-0.29% 729/3014 |
16.43% 1458/3129 |
-2.39% 2066/3463 |
| 2023 | -8.54% 1025/2656 |
0.86% 1679/2280 |
-4.45% 1173/2385 |
1.73% 284/2515 |
-6.72% 1891/2655 |
| 2022 | -16.72% 506/2207 |
-10.93% 457/1919 |
6.41% 706/2016 |
-13.14% 842/2113 |
1.16% 1360/2208 |
| 2021 | -7.72% 1040/1822 |
-2.49% 654/1255 |
-0.03% 1122/1330 |
-7.26% 1038/1466 |
2.07% 706/1822 |
| 2020 | 23.95% 642/1250 |
-11.25% 827/1028 |
10.41% 769/1067 |
12.66% 374/1164 |
12.28% 484/1184 |
| 2019 | 36.84% 349/1092 |
22.02% 580/754 |
4.27% 33/804 |
2.07% 328/850 |
5.37% 728/918 |
| 2018 | -16.78% 113/834 |
- - |
- - |
- - |
-11.29% 279/691 |
| 2017 | 27.20% 91/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.89% 150/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 天弘上证50ETF联接C VS. 长安沪深300非周期A(740101) |